AstraZeneca's BREZTRI Shows Clinically Meaningful Asthma Results in Lancet Publication
Event summary
- Phase III KALOS and LOGOS trials for AstraZeneca’s BREZTRI (budesonide/glycopyrronium/formoterol fumarate) demonstrated statistically significant and clinically meaningful improvements in patients with uncontrolled asthma.
- BREZTRI improved lung function by 76mL and 90mL in pooled analysis of the trials, compared to dual-combination ICS/LABA therapies.
- The results, published in The Lancet Respiratory Medicine, also showed reductions in severe asthma exacerbations with BREZTRI.
- BREZTRI is already approved for COPD in over 80 countries and regulatory filings for asthma are currently under review in major regions.
The big picture
The KALOS and LOGOS trial results represent a significant advancement in asthma treatment, addressing the unmet need for more effective therapies for patients with uncontrolled disease. With an estimated 262 million people worldwide suffering from asthma, the potential market for BREZTRI is substantial. AstraZeneca’s existing COPD franchise and established commercial infrastructure provide a foundation for a successful asthma launch, but competition and regulatory hurdles remain.
What we're watching
- Regulatory Approval
- The speed of regulatory approvals in major markets will be a key indicator of AstraZeneca’s ability to rapidly expand BREZTRI’s market reach and capture significant revenue.
- Market Adoption
- How quickly physicians and patients adopt BREZTRI, given existing treatment options, will determine the drug’s ultimate commercial success and impact AstraZeneca’s respiratory portfolio.
- Competitive Landscape
- The response from competitors like Symbicort's manufacturer will be crucial; they may accelerate innovation or price adjustments to retain market share.
Related topics